Livagen (Lys-Glu-Asp-Ala): Chromatin Activation in Lymphocytes

Livagen is one of the few bioregulators whose published work tests the family mechanism directly — chromatin activation in lymphocytes from older donors, using human cells rather than a phenotype proxy.

· · 2 min read
livagen bioregulator khavinson Lys-Glu-Asp-Ala KEDA chromatin lymphocytes hepatic

Key Research Findings

  • Livagen is the tetrapeptide Lys-Glu-Asp-Ala (KEDA), classified in the Khavinson family as hepatic-associated.
  • Its strongest paper tests the family mechanism directly: chromatin activation in lymphocytes from older human donors (PMID 12533768).
  • That is unusual — most of the family is argued through phenotype rather than through chromatin itself.
  • The hepatic label is weakly supported: none of the three papers is a liver-function study.
  • The enkephalin study is a combination design with Epitalon, so results cannot be assigned to either alone.
  • Formula C18H31N5O9, 461.47 g/mol — corrected from an earlier catalog value inconsistent with the sequence. No amount is established.

What Livagen Is

Livagen is a synthetic tetrapeptide, Lys-Glu-Asp-Ala (KEDA), classified within the bioregulator family as hepatic-associated.

Its literature is small but unusually direct. Where most of the family is argued through phenotype — a tumour count, a behavioural score — one of the Livagen papers goes straight at the proposed mechanism, and it does so in human cells.

Research use only. Supplied for laboratory research. Not for human or veterinary use. No marketing authorisation exists and no therapeutic claim is made.

What the Published Studies Report

Chromatin activation in human lymphocytes

The central paper reports effects of Livagen on chromatin activation in lymphocytes from old people (Khavinson et al., Bull Exp Biol Med 2002, PMID 12533768).

This matters more than its citation count suggests. The family's proposed mechanism is that short peptides act on DNA and chromatin to modulate transcription. Chromatin decondensation in primary human cells is a direct test of that proposition rather than an inference from a downstream outcome — and the donor age is part of the design, not incidental.

Digestive enzyme activity across ages

A study in Advances in Gerontology examined the effect of Livagen on activity of digestive enzymes in the gastrointestinal tract and non-digestive organs in rats of different ages (Timofeeva et al., 2005, PMID 16075683). The inclusion of non-digestive organs is notable for the same reason the Cortagen heart study is: the design does not assume tissue confinement.

Enkephalin-degrading enzymes

Work examining the effect of Livagen and Epitalon on enkephalin-degrading enzymes in human serum (Kost et al., Izv Akad Nauk Ser Biol 2003, PMID 12942748) is a combination design, so results cannot be assigned to either peptide alone.

Reading the Evidence

The chromatin work is the strongest item because it tests the mechanism directly in human primary cells. It is still a cell-level result.

The hepatic label is weakly supported. Nothing in the three papers is a liver-function study; the association comes from the family classification scheme. If hepatic function is the research question, that gap should be explicit in the design.

No amount is established for any species or context.

Structure and Handling

  • Sequence. Lys-Glu-Asp-Ala (KEDA), tetrapeptide.
  • Formula. C18H31N5O9, 461.47 g/mol.
  • Form. Lyophilised powder, ≥98% purity, third-party certificate of analysis per batch.
  • Storage. Sealed vial at −20 °C, protected from light; reconstituted solution at 2–8 °C.
  • Reconstitution. Bacteriostatic water down the vial wall, never onto the powder cake. Do not shake. See the reconstitution calculator.

The catalog record for this compound previously carried a molecular formula inconsistent with the stated sequence. It has been corrected against the sequence and verified. If you sourced material against the earlier figure, check the certificate of analysis for the batch you hold.

Ovagen shares the hepatic association but has no study naming it. Epithalon appears alongside Livagen in the enkephalin work. Full family on the bioregulator overview.

Frequently Asked Questions

What is Livagen?

Livagen is a synthetic tetrapeptide, Lys-Glu-Asp-Ala (KEDA), classified within the Khavinson bioregulator family as hepatic-associated. It has three published papers naming it directly.

What does the Livagen chromatin research show?

A 2002 study reports effects on chromatin activation in lymphocytes from older donors (PMID 12533768). This is a direct test of the family proposed mechanism — that short peptides act on DNA and chromatin to modulate transcription — carried out in primary human cells rather than inferred from a downstream phenotype.

Is the hepatic association supported by the research?

Weakly. None of the three papers naming Livagen is a liver-function study; the hepatic label comes from the family classification scheme. If hepatic function is the research question, that gap should be explicit in the design.

Is there an established Livagen dosage?

No. No controlled human programme exists, so no published figure is available for any population or context.

What is the molecular formula of Livagen?

C18H31N5O9, molecular weight 461.47 g/mol, derived from the Lys-Glu-Asp-Ala sequence and cross-checked against the residue composition. Our catalog previously carried a formula inconsistent with that sequence; it has been corrected. If you sourced material against the earlier figure, check the certificate of analysis for the batch you hold.

References

  1. Khavinson VKh, Lezhava TA, Monaselidze JR, Jokhadze TA, Dvalishvili NA, Bablishvili NK, et al.. Effects of Livagen peptide on chromatin activation in lymphocytes from old people Bulletin of Experimental Biology and Medicine (2002)
  2. Timofeeva NM, Gordova LA, Nikitina AA, Gromova LV. Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages Advances in Gerontology (2005)
  3. Kost NV, Sokolov OY, Gabaeva MV, Zolotarev YA, Malinin VV, Khavinson VKh. Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum Izvestiia Akademii Nauk, Seriia Biologicheskaia (2003)
Research Use Only: This content is intended for laboratory and scientific research purposes only. It is not intended for human use, medical advice, diagnosis, or treatment. All compounds discussed are for in vitro and preclinical research contexts.

Related Articles

Prostamax (Lys-Glu-Asp-Pro): Chromatin Effects in Human Lymphocytes

Aug 6, 2026 · 2 min

Cardiogen (Ala-Glu-Asp-Arg): Myocardial Tissue Culture and a Sarcoma Model

Aug 6, 2026 · 2 min

Bronchogen (Ala-Glu-Asp-Leu): DNA Thermostability and a Sequence Discrepancy

Aug 6, 2026 · 2 min